Clinical Science Advisory Board Members

All advisory board members will assist with the annual stakeholder meeting; website outreach to professionals and patients; assist CCF to acquire CME funding to educate the general medical community; provide administrative guidance, assistance and strategic direction; other responsibilities to be determined.

Chair, Alan P. Venook, MD

Dr. Alan Venook is the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco (UCSF) and is the Shorenstein Associate Director for Program Development at the Helen Diller Family Comprehensive Cancer Center at UCSF.  Dr. Venook received a BA in Biological Sciences from Rutgers College in 1976, his MD Degree in 1980 from UCSF, completed his internship at UCSF in 1981and then spent two years in the Public Health Service.  He completed residency in Internal Medicine at the University of California, Davis and then returned to UCSF as a Hematology / Oncology Fellow in 1985, joining the faculty in 1988. Dr. Venook’s initial clinical research projects involved multidisciplinary collaborations to treat tumors via the hepatic artery.  In 1990 he described the UCSF experience with chemoembolization for patients...

Mitesh J. Borad, MD

Dr. Mitesh J. Borad is an Assistant Professor of Medicine and Director of Phase I Drug Development at Mayo Clinic in Arizona. He obtained his internal medical training at Cedars-Sinai Medical Center and completed his medical oncology fellowship at Tulane University School of Medicine. Prior to joining Mayo Clinic, he spent 3 years at the Translational Genomics Research Institute as a Genomics Medicine Scholar. He has been serving on the NCI Hepatobiliary Task Force since 2011. His research and clinical interests are in development of novel treatments for patients with biliary and liver cancers. His team has been engaged in whole genome analysis efforts in cholangiocarcinoma with focus on discovery of novel drug targets and their subsequent implementation in the clinic with the long...

Daniel Catenacci, MD

As an adult medical oncologist, Daniel Catenacci, Assistant Professor of Medicine, specializes in the treatment of gastrointestinal malignancies. He provides skilled care for a range of conditions, including pancreatobiliary, liver (hepatocellular carcinoma), esophageal, gastric, colorectal, appendiceal, neuroendocrine (carcinoid), and anal cancers. Dr. Catenacci works with a multi- disciplinary team of surgical oncologists, radiation oncologists, and medical oncologists to provide the most optimal care possible for cancer patients. An active basic and clinical researcher, Dr. Catenacci is involved in bench-to-bedside translational research. He conducts basic investigations on normal and cancer cell signaling with the ultimate goal of developing new inhibitory drugs for the treatment of biliary, gastroesophageal cancer and other digestive malignancies. Additionally, Dr. Catenacci designs and executes clinical trials based on laboratory findings and...

Anthony B. El-Khoueiry, MD

USC Norris Comprehensive Cancer Center and Hospital Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at the Keck School of Medicine of the University of Southern California. He is currently assistant professor of clinical medicine in the Division of Medical Oncology, a member of the Gastrointestinal Cancers Program and director of the phase I drug development clinical program. He has been the medical director of the Clinical Investigations Support Office at the USC Norris Comprehensive Cancer Center since...

Cristina Ferrone, MD

Dr. Ferrone completed her medical degree at the Washington University School of Medicine St. Louis, her residency at Massachusetts General Hospital and her fellowship Memorial Sloan Kettering Cancer Center. She is currently an Assistant Professor in the Department of Surgery at Harvard Medical School and a surgeon at Mass General who specializes in treating patients with gastrointestinal cancers.  Her lab is exploring the immunologic responses and gene expression patterns of pancreatic adenocarcinoma, pancreatic neuroendocrine tumors, and...

Renuka Iyer, MD

Dr Iyer is an Associate Professor of Oncology and Co-Director of the Liver and Pancreas Tumor Program and Section Chief for Gastrointestinal Oncology for Roswell Park Cancer Institute. Dr. Iyer received her MD at the University of Mumbai, Grant Medical College. She completed her residency at Lincoln Medical and Mental Health Center, Cornell University and her fellowship at Roswell Park Cancer Institute. Her areas of expertise include: Bile duct cancer Carcinoid Cholangiocarcinoma Esophageal cancer Hepatocellular cancer Pancreatic cancer She also has special interest in: Developing novel treatments for patients with hepatocellular, pancreaticobiliary and neuroendocrine cancers Studies of novel targeted therapies in a woodchuck model of liver cancer Understanding the mechanism of the anticancer effects of vitamin...

Vice Chair, Milind Javle, MD

Dr. Javle received his medical degree at Grant Medical College, University of Bombay, in Bombay, India. He then pursued postgraduate training in Internal Medicine at the State University of New York (SUNY) in Buffalo, NY, followed by a clinical fellowship in medical oncology at Roswell Park Cancer Institute in Buffalo, NY. He is a Professor of Gastrointestinal (GI) Medical Oncology at the MD Anderson Cancer Center in Houston, TX. He has served in the past as Assistant Professor of Medical Oncology at Roswell Park Cancer Institute and has been a faculty member at MD Anderson Cancer Center since 2007, in the GI Medical Oncology Division, with research interests in pancreatic and biliary cancers. His research interests include identification of molecular subtypes of pancreatic and...

R. Kate (Katie) Kelley, MD

Dr. Robin K. Kelley is a gastrointestinal oncologist who specializes in hepatobiliary cancers, such as cholangiocarcinoma, hepatocellular carcinoma, and gall bladder cancer, as well as gastrointestinal cancers including gastric cancer, esophageal cancer, colon and rectal cancers, pancreatic cancer, and gastrointestinal stromal tumors. Her research focuses on developing clinical trials of novel therapeutic agents and treatment combinations in hepatocellular carcinoma and biliary tract cancers, closely integrated with translational research using tumor specimens from patients to identify novel biomarkers and therapeutic targets in these challenging cancers of the liver. She works closely with colleagues in surgical oncology, hepatology, interventional radiology, radiation oncology, and the liver transplant program at UCSF. Dr. Kelley was born in Montana and grew up in San Diego, California. She received her undergraduate...

Andrew X. Zhu, MD, PhD

Dr. Andrew X. Zhu is Director of Liver Cancer Research at Massachusetts General Hospital Cancer Center and an Associate Professor of Medicine at Harvard Medical School. The major focus of his research is to develop more effective therapies for hepatocellular carcinoma (HCC) and cholangiocarcinoma through phase I, II and III clinical trials. The second area of his research interests is directed at the development of novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance. The third area of his research is to define and characterize known or novel genetic mutations in HCC and cholangiocarcinoma and assess their potential correlation with clinical outcomes and as therapeutic targets. As a widely published author, Dr. Zhu has served as a principle investigator...